P103: Comparison of PET-derived parameters in program cell death-1 inhibitor and CD30 antibody drug conjugate-based therapies in patients with advanced stage cHL: A single center experience.

P103: Comparison of PET-derived parameters in program cell death-1 inhibitor and CD30 antibody drug conjugate-based therapies in patients with advanced stage cHL: A single center experience.

Bibliographic Details
Main Authors:	Serageldin Kamel, Lucia Martiniova, Eslam Aboismail, Joo Schmidt, Sairah Ahmed, Ranjit Nair, Raphael E. Steiner, Michael L. Wang, Sarita Soebianto, Gregory Ravizzini, Tinsu Pan, Hun Ju Lee
Format:	Article
Language:	English
Published:	Wiley 2022-10-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000890980.06633.66

Similar Items

Current Status of Radiolabeled Monoclonal Antibodies Targeting PSMA for Imaging and Therapy
by: Mohammed Abusalem, et al.
Published: (2023-09-01)

Impact of Tumour Epstein–Barr Virus Status on Clinical Outcome in Patients with Classical Hodgkin Lymphoma (cHL): A Review of the Literature and Analysis of a Clinical Trial Cohort of Children with cHL
by: Mahdi Nohtani, et al.
Published: (2022-09-01)

An overview of cancer/testis antigens expression in classical Hodgkin's lymphoma (cHL) identifies MAGE-A family and MAGE-C1 as the most frequently expressed antigens in a set of Brazilian cHL patients
by: Bortoluzzo Adriana B, et al.
Published: (2011-09-01)

P052: Targeting CSN5/JAB1 oncogene in classical Hodgkin Lymphoma (cHL)
by: Ioanna Xagoraris, et al.
Published: (2022-10-01)

P051: Serum procalcitonin levels in newly diagnosed classical Hodgkin Lymphoma (cHL): Correlation with other inflammatory biomarkers
by: Alexia Piperidou, et al.
Published: (2022-10-01)

P066 (0154) eBEACOPP FOR FRONT-LINE TREATMENT OF PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA (cHL) IN THE REAL WORLD SETTING
Published: (2018-10-01)

The Role of Brentuximab Vedotin (BV) as Second-Line Treatment of Refractory Classical Hodgkin Lymphoma (cHL) in the Era of Pandemic COVID-19
by: Rajabto W, et al.
Published: (2022-06-01)

Brentuximab vedotin + AVD in cHL: cost impact on adverse events, toxicity, second malignancies, end-of-life and subsequent lines of therapy in Italy
by: Francesca Fiorentino, et al.
Published: (2023-10-01)

P013: Outcomes of first-line treatment (FL) of classical Hodgkin lymphoma (cHL) in Argentina: a real life multicenter retrospective study
by: Korin Laura, et al.
Published: (2022-10-01)

P053: The cGAS-STING anti-tumor immune response pathway as a potential therapeutic target in classical Hodgkin Lymphoma (cHL)
by: Ioanna Xagoraris, et al.
Published: (2022-10-01)

P004: Advanced stage classical Hodgkin lymphoma (cHL) patients with a positive interim-PET (PET-2) Deauville score (DS) 5 after 2 ABVD cycles: A pooled analysis of individual patient data of three multicenter trials
by: Simonetta Viviani, et al.
Published: (2022-10-01)

P110: Outcome of high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT) as first salvage treatment for relapsed or refractory classical Hodgkin Lymphoma (cHL) in the era of PET-adapted strategy among Italian centers
by: Simonetta Viviani, et al.
Published: (2022-10-01)

Exploring the landscape of CHL strings on T d
by: Anamaría Font, et al.
Published: (2021-08-01)

Data-driven gated PET/CT: implications for lesion segmentation and quantitation
by: M. Allan Thomas, et al.
Published: (2021-08-01)

Positivity of discrete information for CHL black holes
by: Suresh Govindarajan, et al.
Published: (2023-02-01)

T028 (0163) ALLOGENEIC STEM CELL TRANSPLANTATION (Allo-SCT) FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (cHL) PATIENTS TREATED WITH NIVOLUMAB IS ASSOCIATED WITH AN UNPRECEDENTED LOW RELAPSE RATE
Published: (2018-10-01)

P081 (0084) A CLINICOPATHOLOGIC CONSENSUS STUDY OF GRAY ZONE LYMPHOMA (GZL) WITH FEATURES INTERMEDIATE BETWEEN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AND CLASSICAL HL (CHL)
Published: (2018-10-01)

Synthesis of daunomycin-oligoarginine conjugates and their effect on human leukemia cells (HL-60)
by: Zoltán Bánóczi, et al.
Published: (2008-02-01)

P091 (0159) SERUM sCD30 AND TARC DO NOT CORRELATE WITH PET-BASED RESPONSE ASSESSMENT IN PATIENTS (PTS) WITH STAGE III OR IV CLASSICAL HODGKIN LYMPHOMA (cHL): PHASE 3 ECHELON-1 STUDY OF BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY VS CHEMOTHERAPY ALONE
Published: (2018-10-01)

Fortnightly variability of Chl <i>a</i> in the Indonesian seas
by: E. D. Zaron, et al.
Published: (2023-01-01)

Four-derivative couplings and BPS dyons in heterotic CHL orbifolds
by: Guillaume Bossard, Charles Cosnier-Horeau, Boris Pioline
Published: (2017-07-01)

Development of [89Zr]Zr-hCD103.Fab01A and [68Ga]Ga-hCD103.Fab01A for PET imaging to noninvasively assess cancer reactive T cell infiltration: Fab-based CD103 immunoPET
by: Xiaoyu Fan, et al.
Published: (2023-11-01)

BKM Lie superalgebras from counting twisted CHL dyons – II
by: Suresh Govindarajan, et al.
Published: (2019-11-01)

Co-expression of a SARP Family Activator ChlF2 and a Type II Thioesterase ChlK Led to High Production of Chlorothricin in Streptomyces antibioticus DSM 40725
by: Yue Li, et al.
Published: (2020-08-01)

The development of reading comprehension ability of Chinese Heritage Language (CHL) learners in Indonesia
by: Qinling Zhou, et al.
Published: (2024-03-01)

CHL1 and NrCAM are primarily expressed in low grade pediatric neuroblastoma
by: Wachowiak Robin, et al.
Published: (2019-12-01)

ECOSMO II(CHL): a marine biogeochemical model for the North Atlantic and the Arctic
by: V. Ç. Yumruktepe, et al.
Published: (2022-05-01)

Exact effective interactions and 1/4-BPS dyons in heterotic CHL orbifolds
by: Guillaume Bossard, Charles Cosnier-Horeau, Boris Pioline
Published: (2019-09-01)

Differential expression of CHL1 gene during development of major human cancers.
by: Vera N Senchenko, et al.
Published: (2011-03-01)

CHL1 is a selective organizer of the presynaptic machinery chaperoning the SNARE complex.
by: Aksana Andreyeva, et al.
Published: (2010-01-01)

Evolution of light-harvesting complex proteins from Chl <it>c</it>-containing algae
by: Puerta M Virginia, et al.
Published: (2011-04-01)

Effects of temperature and light induction of CHL a fluorescence in situ: An ecophysiological view
by: Nikolić B., et al.
Published: (2008-01-01)

Factors influencing the distribution of Chl-a along coastal waters of East Peninsular Malaysia
by: F. Shaari,, et al.
Published: (2017)

Variability of Chl <i>a</i> Concentration of Priority Marine Regions of the Northwest of Mexico
by: Carlos Manuel Robles-Tamayo, et al.
Published: (2022-09-01)

The Q Motif Is Involved in DNA Binding but Not ATP Binding in ChlR1 Helicase.
by: Hao Ding, et al.
Published: (2015-01-01)

Oscillation kinetics of post-illumination increase in Chl fluorescence in Cyanobacterium Synechocystis PCC 6803
by: Min eXu, et al.
Published: (2016-02-01)

Ezrin interacts with the tumor suppressor CHL1 and promotes neuronal differentiation of human neuroblastoma.
by: Marzia Ognibene, et al.
Published: (2020-01-01)

Exact half-BPS black hole entropies in CHL models from Rademacher series
by: Richard Nally
Published: (2019-01-01)

MicroRNA-Mediated Regulation of ITGB3 and CHL1 Is Implicated in SSRI Action
by: Keren Oved, et al.
Published: (2017-11-01)

KAPACITNÍ MOŽNOSTI TRATI 031 V ÚSEKU PARDUBICE HL. N. – HRADEC KRÁLOVÉ HL. N.
by: Přemysl Šrámek
Published: (2015-04-01)